PROSPECTUS SUMMARY
This summary highlights information appearing in other sections of this prospectus. This summary is not complete and does not contain all of the information you should consider before buying shares in this offering. You should read this entire prospectus carefully, including "Risk Factors" and our consolidated financial statements, before making an investment decision.
MitoKor, Inc.
Our Company
We focus on the discovery and development of drugs for the treatment of major diseases and conditions associated with mitochondrial dysfunction. Mitochondria are specialized cellular substructures that are essential to human life, and according to A Primary Care Physician's Guide, more than 75 diseases have been linked directly or indirectly to mitochondrial dysfunction. We integrate our broad biology and chemistry capabilities to identify mitochondrial drug targets and therapeutic leads and to advance product candidates into the clinic, either independently or in collaboration with our strategic partners. We have one drug in a Phase III clinical trial for Alzheimer's disease and a second drug in Phase I for Parkinson's disease. In addition, we are advancing a number of preclinical lead compounds toward the clinic in stroke, obesity, diabetes, osteoarthritis, glaucoma and other diseases. We currently have agreements with major pharmaceutical and biotechnology companies, including Wyeth (formerly American Home Products Corporation), Pfizer Inc, and Chiron Corporation. We also maintain relationships with numerous academic centers.
Mitochondria generate nearly all of the cell's energy and participate in many cellular pathways, including metabolism and cell death. The tissues of the body that rely most heavily on mitochondria are composed of long-lived, energy demanding cell types, like those found in the brain, muscles and the pancreas. Mitochondrial dysfunction may be an inevitable part of the aging process, and is associated with large patient populations that have significant unmet medical needs. |
